34
Update in the Management of Thyroid Neoplasms David R. Byrd, MD Department of Surgery University of Washington

Update in the Management of Thyroid Neoplasms David R. Byrd, MD Department of Surgery University of Washington

  • View
    219

  • Download
    1

Embed Size (px)

Citation preview

Page 1: Update in the Management of Thyroid Neoplasms David R. Byrd, MD Department of Surgery University of Washington

Update in the Management of Thyroid Neoplasms

David R. Byrd, MD

Department of Surgery

University of Washington

Page 2: Update in the Management of Thyroid Neoplasms David R. Byrd, MD Department of Surgery University of Washington

NCCN - National Comprehensive Cancer Network

• yearly update from the NCI-designated comprehensive cancer centers (FHCRC --> FHCRC + UWMC)

• Consensus guidelines from the NCCN membership institutions

• not focussed on the practice of the community cancer practitioner

Page 3: Update in the Management of Thyroid Neoplasms David R. Byrd, MD Department of Surgery University of Washington

NCCN - Management of Thyroid Carcinoma -2001

Page 4: Update in the Management of Thyroid Neoplasms David R. Byrd, MD Department of Surgery University of Washington

Thyroid Nodule - History

Local Sxs

Risk factors

Function

Page 5: Update in the Management of Thyroid Neoplasms David R. Byrd, MD Department of Surgery University of Washington

Thyroid nodules

• 6-10% adult U.S. population– 5% are malignant

• FNA best initial test - 96% PPV

• U/S good to follow or document MNG

• thyroid scan good if symptoms of hyper- or hypothyroidism or if indeterminate cytology/multinodular goiter

• suppression most successful when TSH high

Page 6: Update in the Management of Thyroid Neoplasms David R. Byrd, MD Department of Surgery University of Washington

FNA Results of Thyroid Nodule

Benign --> F/U 6-12 months

cyst --> F/U 6-12 months

indeterminate --> repeat FNA, I123 scan if same results

follicular neoplasm --> I123 scan or surgery

suspicious --> surgery

carcinoma --> surgery

FNA

Page 7: Update in the Management of Thyroid Neoplasms David R. Byrd, MD Department of Surgery University of Washington

Results of I123 scan

“hot” --> check TFTs

“euthyroid” --> rarely CA, F/U only

“cold”* (still takes up some iodine, though less than normal gland)

*NOTE: 1. Nearly all cancers are “cold” 2. However, only about 10-15%

of “cold” nodules are cancer

I123 scan

Page 8: Update in the Management of Thyroid Neoplasms David R. Byrd, MD Department of Surgery University of Washington

Thyroid Carcinoma - Nodule Evaluation

©National Comprehensive Cancer Network

Page 9: Update in the Management of Thyroid Neoplasms David R. Byrd, MD Department of Surgery University of Washington

Thyroid Carcinoma - Nodule Evaluation

©National Comprehensive Cancer Network

Page 10: Update in the Management of Thyroid Neoplasms David R. Byrd, MD Department of Surgery University of Washington

Pathology of Thyroid Cancer• differentiated thyroid cancer (DTC):

– papillary - commonly spreads to nodes (40-50%), excellent prognosis

– mixed - papillary and follicular - acts like papillary, excellent prognosis

– follicular - slightly worse than papillary, can spread to bone, less to nodes (15%); Hurthle cell Ca is variant

• medullary - sporadic vs. familial (MEN 2A), total thyroidectomy is treatment

• anaplastic - aggressive and fatal, surgical role is biopsy only

Page 11: Update in the Management of Thyroid Neoplasms David R. Byrd, MD Department of Surgery University of Washington

Thyroid Carcinoma - Papillary Carcinoma

©National Comprehensive Cancer Network

Page 12: Update in the Management of Thyroid Neoplasms David R. Byrd, MD Department of Surgery University of Washington

Rationale for Total Thyroidectomy for DTC

• improved effectiveness for I131 ablation• lowers dose needed forI131 ablation• allows f/u w/ thyroglobulin levels• decreased recurrence• improved survival in high risk pts.

• decreased risk of pulmonary mets and dedifferentiated CA

Page 13: Update in the Management of Thyroid Neoplasms David R. Byrd, MD Department of Surgery University of Washington

Rationale Against Total Thyroidectomy for DTC

• increased RLN injury and hypoparathyroidism• contralateral disease not clinically relevant• survival nearly equivalent for low risk patients• I131 ablation not necessary for most patients• thyroglobulin levels not necessary for most

patients

Page 14: Update in the Management of Thyroid Neoplasms David R. Byrd, MD Department of Surgery University of Washington

Thyroidectomy for DTC - Technique

• know the anatomy

• protect RLN

• preserve all parathyroids

• know when to reassess or quit

Page 15: Update in the Management of Thyroid Neoplasms David R. Byrd, MD Department of Surgery University of Washington
Page 16: Update in the Management of Thyroid Neoplasms David R. Byrd, MD Department of Surgery University of Washington

Thyroid Carcinoma - Papillary Carcinoma

©National Comprehensive Cancer Network

Page 17: Update in the Management of Thyroid Neoplasms David R. Byrd, MD Department of Surgery University of Washington

Lymphadenectomy for Papillary or Mixed Thyroid CA

RLN

parathyroid

Page 18: Update in the Management of Thyroid Neoplasms David R. Byrd, MD Department of Surgery University of Washington

Thyroid Carcinoma - Papillary Carcinoma

©National Comprehensive Cancer Network

Page 19: Update in the Management of Thyroid Neoplasms David R. Byrd, MD Department of Surgery University of Washington

Thyroid Carcinoma - Papillary Carcinoma

©National Comprehensive Cancer Network

Page 20: Update in the Management of Thyroid Neoplasms David R. Byrd, MD Department of Surgery University of Washington

Thyroid Carcinoma - Papillary Carcinoma

©National Comprehensive Cancer Network

Page 21: Update in the Management of Thyroid Neoplasms David R. Byrd, MD Department of Surgery University of Washington

Thyroid Carcinoma - Papillary Carcinoma

©National Comprehensive Cancer Network

Page 22: Update in the Management of Thyroid Neoplasms David R. Byrd, MD Department of Surgery University of Washington

Thyroid Carcinoma - Follicular Carcinoma

©National Comprehensive Cancer Network

Page 23: Update in the Management of Thyroid Neoplasms David R. Byrd, MD Department of Surgery University of Washington

Thyroid Carcinoma - Follicular Carcinoma

©National Comprehensive Cancer Network

Page 24: Update in the Management of Thyroid Neoplasms David R. Byrd, MD Department of Surgery University of Washington

Thyroid Carcinoma - Follicular Carcinoma

©National Comprehensive Cancer Network

Page 25: Update in the Management of Thyroid Neoplasms David R. Byrd, MD Department of Surgery University of Washington

Thyroid Carcinoma - Follicular Carcinoma

©National Comprehensive Cancer Network

Page 26: Update in the Management of Thyroid Neoplasms David R. Byrd, MD Department of Surgery University of Washington

Thyroid Carcinoma - Follicular Carcinoma

©National Comprehensive Cancer Network

Page 27: Update in the Management of Thyroid Neoplasms David R. Byrd, MD Department of Surgery University of Washington

? Residual Thyroid Cancer• 25 y/o woman with papillary thyroid cancer

– Capsular penetration– Lymph nodes not sampled

• Dx and Post-Rx (200 mCi) I-131 scans show thyroid remnant only– TG off TSH = 110 ng/dL

• Dx I-131 scan 1 year later negative– TG off TSH is still 100 ng/dL

Page 28: Update in the Management of Thyroid Neoplasms David R. Byrd, MD Department of Surgery University of Washington

Thyroid CancerPost therapy (10/98)

2055870

Tc-99m markers

I-131window

Page 29: Update in the Management of Thyroid Neoplasms David R. Byrd, MD Department of Surgery University of Washington

Thyroid CancerDiagnostic Scan (7/99)

2055870

Tc-99m markers

I-131window

Page 30: Update in the Management of Thyroid Neoplasms David R. Byrd, MD Department of Surgery University of Washington

? Residual Thyroid Cancer:FDG PET Scan 8/99

2055870

L Cervical Lymph Nodes

? Central Lymph Nodes

Page 31: Update in the Management of Thyroid Neoplasms David R. Byrd, MD Department of Surgery University of Washington

Case 1

• 60F undergoes L thyroid lobectomy for a solitary nodule w/ follicular cells on FNAC.

• Final path shows 2cm follicular adenoma and incidental 5mm papillary thyroid CA

• ?further management

Page 32: Update in the Management of Thyroid Neoplasms David R. Byrd, MD Department of Surgery University of Washington

Case 1 - issues

• ? Completion thyroidectomy --> NO

• ? Radioactive iodine therapy --> NO

• ? Thyroid suppression --> +/-

• ? F/u -6 month intervals with H & P

Result: the 2 cm nodule is benign and the 0.5cm nodule is an incidental carcinoma of minimal significance

Page 33: Update in the Management of Thyroid Neoplasms David R. Byrd, MD Department of Surgery University of Washington

Case 2

• 40M w/ solitary 1.5cm L thyroid nodule on exam

• h/o neck irradiation for enlarged thymus as child

• ?further management

Page 34: Update in the Management of Thyroid Neoplasms David R. Byrd, MD Department of Surgery University of Washington

Case 2 - Issues

This is a setting of higher risk of cancer - male, solitary lesion, and equivocal hx of neck irradiation:

minimal operation is thyroid lobectomy + isthmusectomy, proceed to total or subtotal thyroidectomy if bilateral nodules and/or if carcinoma found

frozen section is notoriously unable to definitively call carcinoma - therefore permanent pathology usually necessary to confirm carcinoma